Hansoh Pharma’s shares jumped 13% after reporting that more than 85% of its revenue now comes from innovative medicines, highlighting the rapid growth of China’s home‑grown drug sector. One of the headline drugs costs roughly $475,000 per patient, reflecting the huge R&D investment—often over $1 billion and a decade of work—required to bring a new therapy to market. In other breakthroughs, Akeso’s experimental antibody Ivonescimab (Yidafang) met its primary goal in a Phase III trial for advanced biliary‑tract cancer, showing a clear survival benefit and strong results on secondary measures such as progression‑free survival and response rate. Meanwhile, BeiGene’s PD‑1 blocker tislelizumab received U.S. FDA approval for a new combination regimen targeting HER‑2 positive stomach and esophageal cancers. Innovent Biologics announced the first clinical trial approval for IBI3046, an siRNA drug designed to help adults with obesity lose weight by boosting fat breakdown. Across the Pacific, the FDA granted early approval to Revolution Medicines’ RAS inhibitor daraxonrasib, the world’s first drug of its class for pancreatic cancer. China also unveiled its 2026 National Essential Medicines List, expanding the catalog to 794 items and adding GLP‑1RA diabetes drugs, several new cancer antibodies and targeted therapies. The expanded list signals stronger support for cutting‑edge treatments and a more diverse drug market.
Read more